Kiromic BioPharma (Kiromic BioPharma) Goodwill : $0.00 Mil (As of Mar. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Kiromic BioPharma Goodwill?

A Goodwill is an intangible asset that arises as a result of the acquisition of one company by another for a premium value. The value of a company's brand name, solid customer base, good customer relations, good employee relations and any patents or proprietary technology represent goodwill. Kiromic BioPharma's goodwill for the quarter that ended in Mar. 2024 was $0.00 Mil.

Kiromic BioPharma Goodwill Historical Data

The historical data trend for Kiromic BioPharma's Goodwill can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kiromic BioPharma Goodwill Chart

Kiromic BioPharma Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Goodwill

Get a 7-Day Free Trial

Kiromic BioPharma Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Goodwill	Get a 7-Day Free Trial															-	-	-	-	-

Kiromic BioPharma Goodwill Calculation

A Goodwill is an intangible asset that arises as a result of the acquisition of one company by another for a premium value. The value of a company's brand name, solid customer base, good customer relations, good employee relations and any patents or proprietary technology represent goodwill. Goodwill is considered an intangible asset because it is not a physical asset like buildings or equipment. The goodwill account can be found in the assets portion of a company's balance sheet.

Kiromic BioPharma (OTCPK:KRBP) Goodwill Explanation

Goodwill to Asset ratio measures how much goodwill a company is recording compared to the total level of its assets.

It is calculated by dividing goodwill by total assets.

Kiromic BioPharma's Goodwill-to-Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Goodwill-to-Asset (A: Dec. 2023 )	=	Goodwill	/	Total Assets
	=	0	/	12.169
	=

Kiromic BioPharma's Goodwill-to-Asset Ratio for the quarter that ended in Mar. 2024 is calculated as

Goodwill-to-Asset (Q: Mar. 2024 )	=	Goodwill	/	Total Assets
	=	0	/	12.628
	=

If the goodwill-to-asset ratio increases, it can mean that the company is recording a proportionately higher amount of goodwill, assuming total assets are remaining constant. It is generally good to see a company increasing its assets regularly; however, if these increases are coming from intangible assets, such as goodwill, the increases may not be as good.

Increases in the goodwill-to-asset ratio might suggest that a company has been aggressively acquiring other firms or has seen its tangible assets decrease in value. When a large portion of total assets are attributable to intangible assets (such as goodwill), the company may be at risk of having that portion of its asset base wiped out quickly if it must record any goodwill impairments. Decreases in the goodwill-to-assets ratio suggest that the company has either written down some goodwill or increased its tangible assets.

Asset needs vary from industry to industry. This is why comparing goodwill-to-assets ratios is generally most meaningful among companies within the same industry. By comparing a company's goodwill to assets ratio to those of other companies within the same industry, investors can get a feel for how a company is managing its goodwill.

Kiromic BioPharma Goodwill Related Terms

Thank you for viewing the detailed overview of Kiromic BioPharma's Goodwill provided by GuruFocus.com. Please click on the following links to see related term pages.

Kiromic BioPharma (Kiromic BioPharma) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Kiromic BioPharma Inc (OTCPK:KRBP) » Definitions » Goodwill

Comparable Companies

Traded in Other Exchanges

N/A

Address

7707 Fannin Street, Suite 140, Houston, TX, USA, 77054

Website

https://www.kiromic.com

Kiromic BioPharma Inc is a biotechnology company. It is an artificial intelligence (AI) driven, end-to-end allogeneic cell therapy company, currently developing the multi-indication allogeneic T cell therapy that exploits the natural potency of the Gamma Delta T cell (GDT) to target solid tumors. The company is a gene-editing which utilizes artificial intelligence and a proprietary neural network platform with a therapeutic focus on immuno-oncology.

Executives

Brian Hungerford	officer: CFO	7707 FANNIN, SUITE 140, HOUSTON TX 77054
Pamela Misajon	director	7707 FANNIN ST, SUITE 140, HOUSTON TX 77054
Michael Catlin	director	7707 FANNIN ST, SUITE 140, HOUSTON TX 77054
Karen Reeves	director	7707 FANNIN, SUITE 140, HOUSTON TX 77054
Francis X Tirelli	director	7707 FANNIN, SUITE 140, HOUSTON TX 77054
Daniel Grant Clark	officer: Interim CFO	7707 FANNIN, SUITE 140, HOUSTON TX 77054
Internati Maurizio Chiriva	director, officer: Chairman, CEO, and President	7707 FANNIN, SUITE 140, HOUSTON TX 77054
Michael Charles Ryan	officer: Chief Technology Officer	7707 FANNIN, SUITE 140, HOUSTON TX 77054
Ignacio Nunez	officer: See Remarks	7707 FANNIN, SUITE 140, HOUSTON TX 77054
Jerry A. Schneider	director	ONE VISION DRIVE, NATICK MA 01760
Michael Nagel	director	C/O VASCULAR SOLUTIONS INC, 6464 SYCAMORE COURT NORTH, MINNEAPOLIS MN 55369
Pietro Bersani	director	C/O FUEL SYSTEMS SOLUTIONS, INC., 780 THIRD AVE. 25TH FLOOR, NEW YORK NY 10017
Scott Dahlbeck	officer: Chief Medical Officer	7707 FANNIN, SUITE 140, HOUSTON TX 77054
Americo Cicchetti	director	7707 FANNIN, SUITE 140, HOUSTON TX 77054
Gianluca Rotino	director, officer: CSIO	7707 FANNIN, SUITE 140, HOUSTON TX 77054